Company Insights

ICCM customer relationships

Explore interactive graphBrowse insights index
ICCM customer relationship map

IceCure Medical (ICCM) — customer map and commercial implications

IceCure Medical sells the ProSense® cryoablation system to hospitals, imaging centers and through exclusive distributors in target markets; revenue is generated from device sales, procedures enabled by those devices and distribution agreements. The company is still in early commercial scale: growth is driven by anchor hospital installs and a limited set of distributor relationships rather than broad consumables recurring revenue. For investors and operators, the customer list below shows how IceCure is converting clinical evidence into targeted commercial placements and regulatory partnerships. If you want a consolidated view of IceCure's commercial footprint and related research, start here: https://nullexposure.com/.

How IceCure sells value and where it makes money

IceCure monetizes primarily through one-time system sales (ProSense®) and associated procedural revenue and services, supplemented by exclusive distribution agreements in strategic geographies. The company positions ProSense as a minimally invasive alternative to surgery for selected breast and kidney tumors; commercial traction depends on clinical endorsements, local regulatory clearance, and hospital purchasing decisions. Company disclosures and press releases show a dual go-to-market model: direct sales to U.S. hospitals and channel distribution in markets like Japan through Terumo.

Operating-model signals to consider as a whole:

  • Contracting posture: a hybrid commercial approach — direct hospital sales in the U.S. plus exclusive distributor contracts abroad (company-level signal).
  • Concentration: revenue remains concentrated and modest, with individual hospital purchases and a single large distributor representing a disproportionate share of international reach.
  • Criticality to customers: ProSense is clinically differentiated for specific procedures but is not a hospital’s core revenue driver; adoption depends on physician champions and clinical data.
  • Commercial maturity: early commercial stage with anchor installs and ongoing regulatory work forming the path to scale.

For a tactical overview of relationships and named customers below, see our detailed mapping. If you want updates on customer wins and regulatory progress, visit https://nullexposure.com/.

Anchor installs in Alabama — Thomas Hospital and its foundation

Thomas Hospital of Fairhope, Alabama — IceCure announced that Thomas Hospital of Fairhope purchased and installed a ProSense system and became the first facility in Alabama to offer breast cancer cryoablation, signaling a regional market entry for the product (PR Newswire, FY2026).
According to the company press release, the install is part of the Infirmary Health network rollout and positions the hospital to offer ProSense-based procedures (PR Newswire, Feb 2026).

Thomas Hospital of Infirmary Health — The hospital is referenced interchangeably with Thomas Hospital of Fairhope in company communications, and IceCure characterized the install as an Infirmary Health system placement that expands procedural availability in the region (Finviz coverage and PR Newswire, FY2025–FY2026).

Thomas Hospital Foundation — IceCure noted that the Thomas Hospital Foundation supported the purchase to advance access to state-of-the-art treatments, indicating philanthropic capital can be a facilitator for initial installs in community hospitals (SAHM Capital and PR Newswire, FY2026).

Regional imaging partner — Shero Imaging (Missouri)

Shero Imaging — IceCure announced that Shero Imaging is the first provider in Missouri to offer breast cancer cryoablation procedures with ProSense, establishing a non-hospital imaging center as a procedural site and expanding the types of facilities that can adopt the system (Finviz news, FY2025–FY2026). This placement highlights a strategy of seeding non-traditional sites of care to broaden access.

Clinical partners and academic endorsements in Japan

Kameda Medical Center — A ProSense user and venue for independent study presentations, Kameda Medical Center hosted presentations of long-term clinical data by a leading breast surgeon using ProSense in a cohort study spanning 2006–2023 (PR Newswire, FY2025). Clinical endorsement at high-volume centers supports adoption and hospital purchasing decisions.

St. Marianna University School of Medicine — A study led by Professor Hisanori Kawamoto at St. Marianna reported zero local breast cancer recurrences at five years following ProSense treatment in the cohort cited by the company, an assertion IceCure has publicly highlighted as part of its clinical evidence package (PR Newswire, FY2025).

The Japan distributor — Terumo Corporation

Terumo Corporation (TRUMF / TRUMY) — Terumo is IceCure’s exclusive distributor in Japan and is the strategic commercial partner responsible for regulatory filings and market rollout. IceCure disclosed $100,000 of revenue tied to the exclusive distribution agreement in the first nine months of 2024, while comparable distributor revenue was not booked in the first nine months of 2025, as reported on the company’s Q3 2025 earnings call transcript (InsiderMonkey, 2025 Q3).
Terumo is also the party expected to submit a PMDA application for breast cancer indication for ProSense; company announcements first referenced an end-2025 submission target and later commentary revised the timing toward first-half 2026 in company communications and the Q3 2025 call (PR Newswire and company letter to shareholders, FY2025–FY2026).

What this customer map implies for investors

  • Evidence-driven commercial traction: installs at Thomas Hospital, Shero Imaging and clinical centers like Kameda and St. Marianna show IceCure is leveraging positive study results to win anchor placements and local champions. Those installs are highly valuable for marketing and clinician training, but they do not yet demonstrate broad commercial pull.
  • Distributor reliance and regulatory gating: the Terumo relationship is critical for Japan access; regulatory submissions handled by a large medical-device distributor accelerate market entry but also concentrate counterparty risk.
  • Revenue concentration and scale risk: reported device revenue and the $100k distributor-related revenue figure indicate current revenues remain small and lumpy, dependent on individual sales and timing of regulatory-driven adoption.
  • Adoption pathway: clinical endorsements and early non-hospital procedural sites (e.g., imaging centers) provide a credible path to scale, but conversion from evidence to recurring procedural volume is the next execution test.

If you want a deeper breakdown of customer relationships and commercial progress, check the company summary and relationship timelines at https://nullexposure.com/.

Final investment takeaways and next steps

IceCure’s customer relationships show early but tangible commercialization: anchor hospital installs, specialist academic endorsements and an exclusive distributor arrangement in Japan form a coherent go-to-market strategy. The key value drivers for investors are continued regulatory milestones (PMDA), steady hospital and imaging-center installs, and the transition from lumpy device sales to predictable procedural volumes.

For a concise tracker of installs, regulator filings and partner disclosures, visit our homepage and sign up for updates: https://nullexposure.com/.

If you need a custom briefing or a comparative map against peer device commercialization trajectories, contact us through https://nullexposure.com/ — we maintain active monitoring of customer wins, regulatory filings and clinical publications.